126937-42-6

Basic information

• Product Name: METHYL N-4-BOC-N-1-CBZ-2-PIPERAZINECARBOXYLATE
• Synonyms: 4-N-BOC-1-N-CBZ-PIPERAZINE-2-CARBOXYLIC ACID METHYL ESTER;METHYL N-4-BOC-N-1-CBZ-2-PIPERAZINECARBOXYLATE;METHYL 4-N-BOC-1-N-CBZ-2-PIPERAZINE CARBOXYLATE;Methyl 4-Boc-1-Cbz-2-piperazinecarboxylate;1-(Benzyloxycarbonyl)-2-(methoxycarbonyl)-4-(tert-butoxycarbonyl)-piperazine;Methyl 1-(benzyloxycarbonyl)-4-(tert-butyloxycarbonyl)piperazine-2-carboxylate
• CAS NO: 126937-42-6
• Molecular Formula: C₁₉H₂₆N₂O₆
• Molecular Weight: 378.42
• Product Categories: pharmacetical
• Mol File: 126937-42-6.mol

Chemical Properties

• Boiling Point: 476.9°C at 760 mmHg
• Flash Point: 242.2°C
• Appearance: /
• Density: 1.214g/cm³
• Vapor Pressure: 2.93E-09mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -1.49±0.70(Predicted)
• CAS DataBase Reference: METHYL N-4-BOC-N-1-CBZ-2-PIPERAZINECARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL N-4-BOC-N-1-CBZ-2-PIPERAZINECARBOXYLATE(126937-42-6)
• EPA Substance Registry System: METHYL N-4-BOC-N-1-CBZ-2-PIPERAZINECARBOXYLATE(126937-42-6)

Safety Data

• Hazardous Substances Data: 126937-42-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
METHYL N-4-BOC-N-1-CBZ-2-PIPERAZINECARBOXYLATE is used as an intermediate in the production of various medications for its potential biological activity and versatility in organic synthesis.
Used in Organic Synthesis:
In the field of organic synthesis, METHYL N-4-BOC-N-1-CBZ-2-PIPERAZINECARBOXYLATE is used as a building block for the synthesis of more complex organic molecules, taking advantage of its functional groups for further reactions and modifications.
Used in Drug Development:
METHYL N-4-BOC-N-1-CBZ-2-PIPERAZINECARBOXYLATE is employed in the development of new drugs, leveraging its unique structural features to explore its potential therapeutic applications and properties in medicinal chemistry.

InChI:InChI=1/C19H26N2O6/c1-19(2,3)27-17(23)20-10-11-21(15(12-20)16(22)25-4)18(24)26-13-14-8-6-5-7-9-14/h5-9,15H,10-13H2,1-4H3

Upstream product

• 126937-41-5 1-(benzyloxycarbonyl)-4-(tert-butoxycarbonyl)-2-piperazinecarboxylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 501-53-1 benzyl chloroformate 
• 98-97-5 2-pyrazylcarboxylic acid 
• 129799-08-2 tert-butyl methyl piperazine-1,3-dicarboxylate 
• 77-78-1 dimethyl sulfate 
• 2762-32-5 piperazine-2-carboxylic acid 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 74-88-4 methyl iodide 
• 186581-53-3 diazomethane 
• 128019-59-0 piperazine-1,3-dicarboxylic acid 1-tert-butyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 317365-33-6 1-(benzyloxycarbonyl)-2-hydroxymethyl-4-(tert-butyloxycarbonyl)-piperazine 
• 126937-44-8 2-methyl 1-phenylmethyl 1,2-piperazinedicarboxilate, trifluoroacetate 
• 126937-41-5 1-(benzyloxycarbonyl)-4-(tert-butoxycarbonyl)-2-piperazinecarboxylic acid 
• 1313517-77-9 1-benzyl 4-tert-butyl 2-methyl 2-ethylpiperazine-1,2,4-tricarboxylate 
• 218952-60-4 2-Pyridin-2-ylmethyl-piperazine-1,2,4-tricarboxylic acid 1-benzyl ester 4-tert-butyl ester 2-methyl ester 

Relevant articles and documents

SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME

Disclosed are compounds, and pharmaceutically acceptable salts thereof, that can ameliorate or treat a viral infection in a subject in need thereof. The disclosure also includes conjugates of such compounds with a protease.

TRICYCLIC PYRIDONES AND PYRIMIDONES

A compound of Formula (I) is provided: (I) where the variables are defined herein.

ΒETA-CATENIN AND B-CELL LYMPHOMA 9 (BCL9) INHIBITORS

Disclosed are inhibitors for the β-catenin/BCL9 interaction. The inhibitors are selective for β-catenin/BCL9 over β-catenin/cadherin interactions. Methods of using the disclosed compounds to treat cancer are also disclosed.

SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

HETEROCYCLIC COMPOUND

The problem of the present invention is to provide a compound having a superior RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like. The present invention relates to a compound represented by the formula (I): [wherein each symbol is as described in the DESCRIPTION] or a salt thereof, which has an RORγt inhibitory action, and useful as a prophylactic or therapeutic agent for psoriasis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, multiple sclerosis, uveitis, asthma, ankylopoietic spondylarthritis, systemic lupus erythematosus, chronic obstructive pulmonary disease or the like.

Novel 6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis B virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R6, X, Y, W and n are as described herein, compositions including the compounds and methods of using the compounds.

Selective and brain-permeable polo-like kinase-2 (Plk-2) inhibitors that reduce α-synuclein phosphorylation in rat brain

Polo-like kinase-2 (Plk-2) has been implicated as the dominant kinase involved in the phosphorylation of α-synuclein in Lewy bodies, which are one of the hallmarks of Parkinson's disease neuropathology. Potent, selective, brain-penetrant inhibitors of Plk

PTERIDINONES AS INHIBITORS OF POLO - LIKE KINASE

The present invention provides compounds having a structure according to Formula (I) or a salt or solvate thereof, wherein ring A, X, R1, R2, R3, R4, R5 and R6, are defined herein. The invention further provides pharmaceutical compositions including the compounds of the invention and methods of making and using the compounds and compositions of the invention, e.g., in the treatment and prevention of various disorders, such as Parkinson's disease.

SATURATED BICYCLIC HETEROCYCLIC DERIVATIVES AS SMO ANTAGONISTS

The present invention relates to compounds of formula I: and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smoantagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

4-ACYL-PIPERAZINES AS ANTI-VIRAL AGENTS

Anti-viral agents of Formula (I) wherein: A represents hydroxy or -NH2; D represents aryl or heteroaryl; E represents hydrogen, straight or branched chain C1-6alkyl, -CO2R1, -C(O)R1a, -C(O)NR2/s